VF
CERO

Virtu Financial’s CERo Therapeutics CERO Stock Holding History

Virtu Financial’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16
Closed -$314K – 2224
2022
Q3 		$314K Buy
+16
New +$322K 0.03% 610

Other funds holding CERO

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Virtu Financial's CERO Position: Q4 2022 in Review

Virtu Financial sold out of CERo Therapeutics (CERO) in Q4 2022, closing a stake of 16 shares — an estimated $314K sold.

Virtu Financial first reported a position in CERO in Q3 2022 and held it in 1 quarter. The position peaked at $314K in Q3 2022. 45 funds tracked by Wall St. Rank hold CERO as of Q4 2022.

  • Virtu Financial reported no remaining CERo Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Virtu Financial sold 16 CERo Therapeutics shares in Q4 2022, an estimated $314K.
  • Virtu Financial first reported a position in CERo Therapeutics in Q3 2022 and held it in 1 quarter.
  • Virtu Financial's CERo Therapeutics position peaked at $314K in Q3 2022.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.